|
Real-time Estimate
Cboe Europe
10:38:41 2026-09-22 EDT
|
5-day change | 1st Jan Change | ||
| 116.02 CHF | -0.10% |
|
+1.56% | +5.49% |
| 10:30am | European Pharma Leaders Push for National Reforms to Boost Investment | DJ |
| 09:41am | European drugmakers call for faster trials, more spending to compete with US, China | RE |
| Market Cap | 269B 234B 221B 201B 377B 25,753B 377B 2,644B 1,019B 13,119B 1,010B 987B 42,333B | P/E 2026 * |
20x | P/E 2027 * | 16.8x |
|---|---|---|---|---|---|
| Enterprise Value | 300B 262B 247B 225B 421B 28,779B 422B 2,954B 1,139B 14,660B 1,128B 1,103B 47,306B | EV / Sales 2026 * |
5.21x | EV / Sales 2027 * | 4.84x |
| Free-Float |
91.66% | Yield 2026 * |
3.08% | Yield 2027 * | 3.21% |
| Markets | Quality | ||
|---|---|---|---|
Swiss Exchange
| NOVN | Delayed | |
CBOE
| 0QLR | Real-time | |
|
London S.E.
| 0QLR | Delayed | |
|
Borsa Italiana
| 1NOVN | End-of-day quote | |
|
Xetra
| NOT | Delayed | |
|
Tradegate
| NOT | Real-time | |
|
Xetra
| NOT | End-of-day quote | |
|
Deutsche Boerse AG
| NOT | Delayed | |
|
Deutsche Boerse AG
| NOT | End-of-day quote | |
|
OTC Markets
| NVSEF | Delayed | |
|
Boerse Muenchen
| NOT | Real-time | |
|
Börse Stuttgart
| NOT | Delayed | |
|
Mexican S.E.
| NOVN N | End-of-day quote | |
|
CBOE
| 0QLR | Real-time | |
|
Wiener Boerse
| NOVN | End-of-day quote | |
|
CBOE
| Real-time |
Last Transcript: Novartis AG
| 1 day | -0.07% | ||
| 1 week | +1.56% | ||
| Current month | -6.20% | ||
| 1 month | -8.79% | ||
| 3 months | -3.87% | ||
| 6 months | -0.43% | ||
| Current year | +5.49% |
| 1 week | 113.48 |  | 116.98 |
| 1 month | 110.3 | | 132.68 |
| Current year | 107.68 | | 132.68 |
| 1 year | 96.8 | | 132.68 |
| 3 years | 81.1 | | 132.68 |
| 5 years | 72.84 | | 132.68 |
| 10 years | 65.09 | | 132.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 2018-01-31 | |
Mukul Mehta
DFI | Director of Finance/CFO | - | 2026-03-15 |
Karen Hale
CMP | Compliance Officer | 58 | 2025-04-13 |
| Director | Title | Age | Since |
|---|---|---|---|
Nancy Andrews
BRD | Director/Board Member | 67 | 2014-12-31 |
| Director/Board Member | 69 | 2015-12-31 | |
Ton Büchner
BRD | Director/Board Member | 61 | 2015-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 5/18/26 | Sell | -5,200 | 0.0003% | |||
| 5/4/26 | Sell | 6,800 | 0.0003% | |||
| 2/17/26 | Sell | 30,743 | 0.0015% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.10% | +1.56% | +17.62% | +25.76% | 269B | |
| +0.33% | +2.23% | +53.85% | +110.97% | 1,038B | |
| -0.74% | -0.55% | +52.54% | +65.57% | 649B | |
| -0.11% | +0.25% | +18.47% | +72.65% | 467B | |
| -0.64% | +0.36% | +33.49% | +45.11% | 355B | |
| +0.33% | +3.63% | +9.18% | +13.67% | 260B | |
| +2.45% | +6.38% | +39.73% | +49.28% | 213B | |
| -0.01% | -6.49% | -32.67% | -59.78% | 176B | |
| -0.01% | +2.38% | +33.15% | +99.67% | 187B | |
| +0.34% | +0.67% | +15.37% | -15.16% | 158B | |
| Average | +0.25% | +0.95% | +24.07% | +40.77% | 377.32B | |
| Weighted average by Cap. | +0.11% | +1.41% | +34.18% | +62.12% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 57.65B 50.27B 47.34B 43.11B 80.84B 5,523B 80.94B 567B 219B 2,814B 217B 212B 9,079B | 61.33B 53.47B 50.36B 45.86B 85.99B 5,875B 86.1B 603B 232B 2,993B 230B 225B 9,658B |
| Net income | 14.2B 12.38B 11.66B 10.62B 19.9B 1,360B 19.93B 140B 53.81B 693B 53.32B 52.14B 2,236B | 15.75B 13.74B 12.94B 11.78B 22.09B 1,509B 22.12B 155B 59.71B 769B 59.17B 57.86B 2,481B |
| Net Debt | 31.58B 27.53B 25.93B 23.62B 44.28B 3,025B 44.33B 311B 120B 1,541B 119B 116B 4,973B | 27.89B 24.31B 22.9B 20.85B 39.1B 2,671B 39.15B 274B 106B 1,361B 105B 102B 4,391B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-22 | CHF 115.64 | -0.43% | 1,717,724 |
| 26-09-21 | CHF 116.14 | +0.90% | 2,020,945 |
| 26-09-18 | CHF 115.10 | -0.79% | 8,399,187 |
| 26-09-17 | CHF 116.02 | +1.52% | 2,407,734 |
| 26-09-16 | CHF 114.28 | +0.39% | 4,101,101 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NOVN Stock
Select your edition
All financial news and data tailored to specific country editions
